-
Clin. Pharmacol. Ther. · Aug 2012
Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
- M Orfali, L Feldman, V Bhattacharjee, P Harkins, S Kadam, C Lo, M Ravi, D T Shringarpure, J Mardekian, C Cassino, and T Coté.
- Specialty Care Business Unit, Pfizer, Cambridge, Massachusetts, USA. may.orfali@pfizer.com
- Clin. Pharmacol. Ther. 2012 Aug 1;92(2):262-4.
AbstractWe compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 vs. 3.5, P < 0.05) and fewer total participants (390 vs. 2,566, P < 0.001), but proportions with randomization, blinding, and placebo-controlled clinical end points were similar, as were development times. We conclude that small studies of appropriate design can support US FDA approval of new medicines for rare diseases.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..